The Online Investor
Daily M&A
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Sat., Apr. 19, 1:18 PM

Slide #3. Actavis Four Products from Akorn

Acquirer: Actavis (NYSE:ACT)
Acquiree: Four Products from Akorn
Details: Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed.

Actavis is a pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic and brand pharmaceutical products. Co. is also developing biosimilar pharmaceutical products, and out-licenses generic pharmaceutical products primarily in Europe through its third-party business. Co. operates in three segments: Actavis Pharma, which its U.S. portfolio consist of approx. 250 generic pharmaceutical product families; Actavis Specialty Brands, which has portfolio of over 40 brand pharmaceutical products; and Anda Distribution, which distributes generic and selected brand pharmaceutical products, vaccines, injectables and over-the-counter medicines.

Open the ACT Page at The Online Investor »

Company Name:  Actavis plc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ACT:  66
Total Market Value Held by ETFs:  $1.40B
Total Market Capitalization:  $34.73B
% of Market Cap. Held by ETFs:  4.04%

Open the ACT Page at The Online Investor (in a new window) »

April 19, 2014    1:18 PM Eastern
Quotes delayed 20 minutes

Trade ACT Now:

Strong Buy (3.81 out of 4)
86th percentile
(ranked higher than approx. 86% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.